Copyright
©The Author(s) 2015.
World J Gastroenterol. May 7, 2015; 21(17): 5138-5148
Published online May 7, 2015. doi: 10.3748/wjg.v21.i17.5138
Published online May 7, 2015. doi: 10.3748/wjg.v21.i17.5138
Ref. | Model | Findings |
Komatsu et al[23] | Mouse, early fibrosis (2 wk CCl4) | global and Spp1 promoter hypomethylation |
Tao et al[17] | Rat (12 wk CCl4) and HSC-T6 cell line | 5-aza-2’-deoxycytidine inhibited HSC proliferation and blocked the decreased expressions of RASAL1 |
Mann et al[24] | Rat (5 wk CCl4) HSC and human HSC line | 5-aza-2’-deoxycytidine blocked HSC transdifferentiation and prevented loss of PPARγ expression |
Zeybel et al[12] | Human NAFLD | PPARγ promoter hypermethylation in severe more than mild fibrosis |
Oh et al[25] | Human cirrhotic and HCC tissues | Increased DNMT3a mRNA and hypermeyhylated cell cycle and tumor suppressor genes in cirrhotic but less than in HCC tissues |
Histone mark | Function | Ref. |
H3K9me3 H3K27me3 | MeCP2 binds to the 5' end of PPARγ and promotes methylation of H3K9. MeCP2 stimulates expression of EZH2 and methylation of H3K27 to form a repressive chromatin structure in the 3' exons of PPARγ | Mann et al[16] |
H3K9me2 | Repression of IκBα promoter. 5-azadC treatment of aHSCs increased expression of IκBα and protein | Mann et al[24] |
H3K4 | ASH1 (H3K4 methyltransferase) binds to promoters and 5' end of αSMA, collagen I, TIMP-1 and TGFβ-1 in aHSCs resulting in transcriptional activation of gene expression | Perugorria et al[33] |
H3K4 H3K27 | ASH1 and EZH2 lysin methyltransferases that regualte H3K4 and H3K27 methylation, respectively were upregulated during liver fibrosis progression and downregulated during fibrosis resolution | Atta et al[32] |
miRNA | Function | Ref. |
miR-15b/16 | Downregulated in aHSCs. Restoring miR-16 and miR-15b reduced Bcl-2, and increased expression of caspases 3, 8, and 9 and aHSC apoptosis | Guo et al[87] |
miR-19b | Downregulated in aHSCs and in human fibrotic liver. miR-19b binds to the 3'-UTR of TGF-βRII. miR-19b mimic decreases expression of TGF-βRII, collagen and α-SMA and increases quiescent characteristics | Lakner et al[44] |
miR-21 | Upregulated in PDGF-BB-aHSCs through PTEN/Akt pathway | Wei et al[88] |
miR-21 | Upregulated in cirrhotic patients and rats. Targets the 3'-UTR of SPRY2 and HNF4α mRNAs in human and rat. Downregulating miR-21 suppressed ERK1 signaling, inhibited HSC activation, and blocked EMT in TGFβ1-treated hepatocytes | Zhao et al[45] |
miR-27a/b | Upregulated in cultured-aHSCs. Downregulation of miR-27a/b induced quiesent HSC phenotype. Target Retinoid X receptor α (RXRα) | Ji et al[46] |
miR-29a/b/c | Decreased expression in murine and human fibrotic livers. Serum expression negatively correlated with degree of liver fibrosis in humans | Roderburg et al[48] |
miR-29b | miR-29b overexpression suppressed Col1α1 mRNA and protein | Ogawa et al[43] |
miR-29b | Downregulated during HSC activation in primary culture. miR-29 overexpression attenuated the increased expression of Col1α1 and Col1α2, α-SMA, DDR2, FN1, ITGB1, and PDGFR-β mRNAs, inhibited HSC activation and supressed c-fos mRNA | Sekiya et al[47] |
miR-122 | Downregulated in HCV-induced liver fibrosis. Expression inversly correlated with fibrosis stage | Morita et al[89] |
miR-132 | Downregulated in aHSCs. In quiescent HSCs miR-132 binds and represses MeCP2 transcripts that carry an extended 3'-UTR that includes the miR132 recognition motif. MeCP promotes methylation of H3K27 of PPARγ through stimulation of EZH2 | Mann et al[16] |
miR-150, miR-194 | Both are reduced in aHScs. miR-150 targets c-myb and miR-194 targets rac-1. Both inhibit HSC activation and ECM production via inhibition of c-myb and rac-1 | Venugopal et al[90] |
miR-155 | Decreased expression in aHSCs, sera and liver tissues of cirrhotic patients. MiR-155 interacts with 3'-UTR of TCF4 and AGTR1 mRNAs involved in EMT and ERK1 pathway, repectively | Dai et al[50] |
miR-199/200 | Expression correlated to progression of liver fibrosis | Murakami et al[91] |
miR-214-5p | Upregulated in human and mouse fibrotic liver | Iizuka et al[92] |
miR-221/222 | Upregulated in human liver in a fibrosis progression-dependent manner | Ogawa et al[93] |
miR-335 | Downregulated during HSC activation. Restoring expression of miR-335 inhibited HSC migration and reduced α-SMA and collagen type I | Chen et al[94] |
- Citation: Atta HM. Reversibility and heritability of liver fibrosis: Implications for research and therapy. World J Gastroenterol 2015; 21(17): 5138-5148
- URL: https://www.wjgnet.com/1007-9327/full/v21/i17/5138.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i17.5138